Order Article Reprints

Mocci G, Bodini G, Allegretta L, Cazzato AI, Chiri S, Aragona G, Perazzo P, Ferronato A, Graziani MG, Pagnini C, et al. Adalimumab Biosimilar GP2017 versus Adalimumab Originator in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study. Biomedicines. 2022; 10(8):1799. https://doi.org/10.3390/biomedicines10081799

Mocci, Giammarco, Giorgia Bodini, Leonardo Allegretta, Alessia Immacolata Cazzato, Stefania Chiri, Giovanni Aragona, Patrizia Perazzo, Antonio Ferronato, Maria Giovanna Graziani, Cristiano Pagnini, and et al. 2022. "Adalimumab Biosimilar GP2017 versus Adalimumab Originator in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study" Biomedicines 10, no. 8: 1799. https://doi.org/10.3390/biomedicines10081799

Mocci, G., Bodini, G., Allegretta, L., Cazzato, A. I., Chiri, S., Aragona, G., Perazzo, P., Ferronato, A., Graziani, M. G., Pagnini, C., Zampaletta, C., Graziosi, C., Picchio, M., Elisei, W., Maconi, G., & Tursi, A. (2022). Adalimumab Biosimilar GP2017 versus Adalimumab Originator in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study. Biomedicines, 10(8), 1799. https://doi.org/10.3390/biomedicines10081799